Clinical Trial Update: A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and pharmacological response of MKC253 inhalation powder in adults with Type 2 diabetes mellitus; the trial has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MKC253 inhalation powder

Snippet

Sponsor: Mannkind Corporation | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED